Oral administration of the anti-inflammatory substance triflusal results in the downregulation of constitutive transcription factor NF-κB in the postnatal rat brain

Neuroscience Letters

Volumn 288, Issue 1, 2000, Pages 41-44

  Acarin, Laia ^a   González, Berta ^a   Castellano, Bernardo ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Glial; Inflammation; Non steroid anti inflammatory drugs; Transcription factor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; TRIFLUSAL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; GLIA CELL; HYPOTHALAMUS; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; NEOCORTEX; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN CHEMISTRY; IMMUNOHISTOCHEMISTRY; NEUROGLIA; NEURONS; NF-KAPPA B; RATS; RATS, LONG-EVANS; SALICYLATES;

EID: 0343081535     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)01202-7     Document Type: Article

References (18)

1. Acarin L., González B., Castellano B. Stat3 and NFκB glial expression after excitotoxic damage to the postnatal brain. NeuroReport. 9:1998;2869-2873.
2. Acarin L., González B., Castellano B. STAT3 and NFκB activation precedes glial reactivity in the excitotoxically injured young cortex but not in the corresponding distal thalamic nuclei. J. Neuropathol. Exp. Neurol. 59:2000;151-163.
3. Albensi B.C., Mattson M.P. Evidence for the involvement of TNF and NF-kappa B in hippocampal synaptic plasticity. Synapse. 35:2000;151-159.
4. Baichwal V.R., Baeuerle P.A. Apoptosis: activate NF-κB or die? Curr. Biol. 7:1997;R94-R96.
5. Baldwin A.S.J. The NFκB and IκB proteins: new discoveries and inshights. Ann. Rev. Immunol. 14:1996;649-681.
6. Bayón Y., Alonso A., Sanchez Crespo M. 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation. Br. J. Pharmacol. 126:1999;1359-1366.
7. Carter B.D., Kaltschmidt C., Kaltschmidt B., Offenhäuser N., Böhm-Matthaei R., Baeuerle P.A., Barde Y.-A. Selective activation of NF-κB by nerve growth factor through the neurotrophin receptor p75. Science. 272:1996;542-545.
8. Fernández de Arriba A., Cavalcanti F., Miralles A., Bayon Y., Alonso A., Merlos M., Garcia-Rafanell J., Forn J. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid. Mol. Pharmacol. 55:1999;753-760.
9. Kaltschmidt B., Uherek M., Wellmann H., Volk B., Kaltschmidt C. Inhibition of NF-kappa B potentiates amyloid beta-mediated neuronal apoptosis. Proc. Natl. Acad. Sci. USA. 96:1999;9409-9414.
10. Kaltschmidt C., Kaltschmidt B., Baeuerle P.A. Stimulation of ionotropic glutamate receptors activates transcription factor NF-κB in primary neurons. Proc. Natl. Acad. Sci. USA. 92:1995;9618-9622.
11. Kaltschmidt C., Kaltschmidt B., Neumann H., Wekerle H., Baeuerle P.A. Constitutive NF-κB activity in neurons. Mol. Cell. Biol. 14:1994;3981-3992.
12. Lipton S.A. Janus faces of NF-kappa B: neurodestruction versus neuroprotection. Nat. Med. 3:1997;20-22.
13. McNeely W., Goa K.L. Triflusal. Drugs. 55:1998;823-833. (discussion 834-825).
14. O'Neill L.A.J., Kaltschmidt C. NF-κB: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 20:1997;252-258.
15. Pennisi E. Building a better aspirin. Science. 280:1998;1191-1192.
16. Prasad A.V., Pilcher W.H., Joseph S.A. Nuclear factor-κB in rat brain: enhanced DNA-binding activity following convulsant-induced seizures. Neurosci. Lett. 170:1994;145-148.
17. Ramis J., Mis R., Forn J. Pharmacokinetics of triflusal and its main metabolite in rats and dogs. Eur. J. Drug Metab. Pharmacokinet. 16:1991;261-268.
18. Wu K.K. Biochemical pharmacology of nonsteroidal anti-inflammatory drugs. Biochem. Pharmacol. 55:1998;543-547.